ONO PHARMA USA is pursuing the clinical development of new drug candidates in oncology, immunology, neurology, and specialty research that it aims to commercialize in the U.S. ONO PHARMA USA was established as a subsidiary of ONO Pharmaceutical Co., Ltd., in 1998. ONO was founded in Osaka, Japan, in 1717, and is now a global R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, such as nivolumab, an anti-PD-1 antibody.